Intuitive Surgical (ISRG)

The healthcare leader has seen better times.

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

These two stocks make fantastic long-term holdings.

Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financia...

These investments could help you sleep peacefully at night.

Intuitive Surgical business momentum has been spectacular recently. But what should investors make of the valuation?

Intuitive Surgical has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.4%. The stock now trades at $491.85, marking...

They are down, but they are not out.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - specialty stocks, including Intuitive Surgical (NASDAQ:ISRG) and its peers.

Intuitive Surgical is the example to keep in mind as you watch this sleeper stock and its new surgical robot.

One of the biggest growth stories in medical devices is Intuitive Surgical, but don't overlook the opportunity ahead for this competitor.

The First Trust RBA American Industrial Renaissance ETF targets small and mid-cap U.S. industrial and community banking companies.

Date: February 24, 2026 By: Financial Research Analyst Introduction For years, Medtronic plc (NYSE: MDT) was viewed by Wall Street as a reliable but sluggish giant—a "Dividend Aristocrat" that offered safety but lacked the high-octane growth of its specialized med-tech peers. That narrative is shifting rapidly. Today, February 24, 2026, marks a watershed moment for [...]

In a definitive sign that the medical technology sector has moved past its post-pandemic stagnation, Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for the third fiscal quarter of 2026. On February 17, 2026, the Dublin-based medical device giant announced total revenue of $9.017 billion,

The company's years of beating the market aren't over yet.

Wall Street is overly focused on GLP-1 drugs even as this medical device maker continues to thrive.

Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for its fiscal third quarter of 2026, marking a significant turning point for the medical technology giant. The results, released on February 17, 2026, surpassed analyst expectations and highlighted a robust recovery in elective procedure volumes and a

This stock has climbed in the triple digits in recent years.